within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J01D_OtherBetaLactamAntibacterials.J01DD15_Cefdinir;

model Cefdinir
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_1C_enteral(
    weight = 70,
    F = 0.21,
    Cl = 2.4305555555555558e-05,
    adminDuration = 600,
    adminMass = 300 / 1000000,
    adminCount = 1,
    Vd = 0.00103,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.005666666666666667,
    Tlag = 10.200000000000001);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Cefdinir</td></tr><tr><td>ATC code:</td><td>J01DD15</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>1</td></tr>
    <tr><td>dosage:</td><td>300</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>1.03</td><td>L</td></tr>
    <tr><td>clearance:</td><td>1.25</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Cefdinir is a third-generation oral cephalosporin antibiotic used for the treatment of a variety of bacterial infections including community-acquired pneumonia, bronchitis, sinusitis, pharyngitis, and certain skin infections. It is currently approved and commonly prescribed for both adults and children.</p><h4>Pharmacokinetics</h4><p>Single-dose pharmacokinetic parameters in healthy adult volunteers, following oral administration.</p><h4>References</h4><ol><li><p>Guay, DR (2000). Pharmacodynamics and pharmacokinetics of cefdinir, an oral extended spectrum cephalosporin. <i>The Pediatric infectious disease journal</i> 19(12 Suppl) S141–S146. DOI:<a href=\"https://doi.org/10.1097/00006454-200012001-00002\">10.1097/00006454-200012001-00002</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/11144395/\">https://pubmed.ncbi.nlm.nih.gov/11144395</a></p></li><li><p>Mao, N, et al., &amp; Liu, X (2025). Bioequivalence of cefdinir dispersible tablets in healthy Chinese subjects under fasting and fed conditions: a single-centred, randomized, open, single-dose, two-preparation, two-cycle, two-sequence, double-crossover trial. <i>Naunyn-Schmiedeberg&#x27;s archives of pharmacology</i> 398(6) 6821–6829. DOI:<a href=\"https://doi.org/10.1007/s00210-024-03701-8\">10.1007/s00210-024-03701-8</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39680100/\">https://pubmed.ncbi.nlm.nih.gov/39680100</a></p></li><li><p>Pichichero, ME, et al., &amp; Nicolau, DP (2008). Probability of achieving requisite pharmacodynamic exposure for oral beta-lactam regimens against Haemophilus influenzae in children. <i>Paediatric drugs</i> 10(6) 391–397. DOI:<a href=\"https://doi.org/10.2165/0148581-200810060-00006\">10.2165/0148581-200810060-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/18998749/\">https://pubmed.ncbi.nlm.nih.gov/18998749</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J01DD15 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Cefdinir;
